02269.HK
WuXi Biologics (Cayman) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 49.18
−3.00%Margins
Gross margin
45.3%
EBITDA margin
37.3%
EBIT margin
31.1%
Net margin
21.2%
FCF margin
10.5%
19.2%
Return on equity
14.1%
Return on assets
26.6%
Return on invested capital
0.67x
Asset turnover
HKD 12.0B
Cash from operations
HKD 3.77
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026